Oncofetal Fibronectin mRNA Is Highly Abundant in the Blood of Patients with Papillary Thyroid Carcinoma and Correlates with High-Serum Thyroid-Stimulating Hormone Levels

Wehmeier, Michael; Petrich, Thorsten; Brand, Korbinian; Lichtinghagen, Ralf; Hesse, Eric

doi:10.1089/thy.2009.0332

Cited by 6 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our observations were indeed similar to the subsequent work by the same group (Wehmeier et al, 2010) 27 in that for the disease-free group, the onfFN expression range was wide and the maximum value was higher than the metastatic groups. Their explanation was that their disease-free patients were perhaps in fact harboring disease that was not detected by their follow-up scheme and that the onfFN mRNA was very sensitive for disease detection.…”

Section: Discussionsupporting

confidence: 91%

“…Hence, our metastatic groups were those who had imaging evidence on either 131 I total body scan or computed tomography in addition of having the serum Tg level of > 2 ng/ml. Even with a loose criterion of metastasis, the metastatic group of constituted only 8% of the patients in the study of Wehmeier et al (2010); while in ours the combined metastatic groups constituted 41%, or the group with distant metastasis alone 27%.…”

Section: Discussioncontrasting

confidence: 56%

“…Despite the lack of statistical significance, a "strong trend" to higher expression rates of onfFN-mRNA in patients with metastases was asserted (Wehmeier et al, 2010). Their metastatic group was defined by having serum Tg > 2 ng/ml regardless of negative imaging results.…”

Section: Discussionmentioning

confidence: 99%

“…By including these patients in the work of Wehmeier et al (2010) 27, their group of local residual disease may comprise those with merely normal residual thyroid. The onfFN expression in this group is likely to be similar to those in the disease-free group, whose range and maximum expression were higher than those with distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Serum Oncofetal Fibronectin (onfFN) mRNA in Differentiated Thyroid Carcinoma (DTC): Large Overlap between Disease-Free and Metastatic Patients

Sritara¹,

Charoenphun²,

Ponglikitmongkol³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim: This study assessed if onfFN mRNA in the peripheral blood of patients with DTC can identify individuals with metastatic disease. Methods: Comparison of onfFN mRNA was made among 3 groups: disease-free, lymph node metastasis, and distant metastasis using real-time RT-PCR on 5 ml blood samples from each DTC patient. Results: Fifty-one patients were included: 30 (59%) were disease-free; 7 (13.7%) had lymph node metastasis; and 14 (27.5%) had distant metastasis. OnfFN mRNA levels in the 3 groups were significantly different (P=0.001) but with a large overlap and the expression being highest in the disease-free group. Subgroup analysis of the metastatic groups did not show any effect of age, cell type, and serum TSH, Tg, and antiTg on onfFN mRNA. The within-run and between-run root mean square coefficients of variations were <2%. Conclusion: OnfFN mRNA in patients with DTC cannot identify those with metastatic disease.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Oncofetal Fibronectin (onfFN) mRNA in Differentiated Thyroid Carcinoma (DTC): Large Overlap between Disease-Free and Metastatic Patients

Sritara¹,

Charoenphun²,

Ponglikitmongkol³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The authors suggested that onfFN mRNA analysis may be a specific tool for monitoring micrometastases in the context of minimal residual disease or for assessing tumor response to therapy. Continuing their studies they performed the analysis of mRNA level in peripheral blood of PTC patients who were previously treated by thyreoidectomy and treated by levothyroxine to determine if onfFN levels are correlated with the status of the disease or with thyroid-stimulating hormone (TSH) serum concentrations (Wehmeier et al 2010). The mean value of onfFN mRNA in bloods from healthy subjects was used as control.…”

Section: Fibronectinmentioning

confidence: 99%

Glycosylation and Glycoproteins in Thyroid Cancer: A Potential Role for Diagnostics

Krześlak¹,

Jóźwiak²,

Lipińska³

2012

Updates in the Understanding and Management of Thyroid Cancer

View full text Add to dashboard Cite

Glycosylation is the most common and the most diverse form of co-and post-translational modifications. An analysis of the Swiss-PROT database has led to the estimation that more than 50% of all proteins are glycosylated. Genes coding proteins involved in all types of oligosaccharides biosynthesis represent 0.5 to 1% of the translated genome (Dennis et al., 1999). Glycoproteins are found ubiquitously in an organism either as soluble (intracellular or extracellular) or as membrane bound molecules. There is a great structural variety of glycoproteins based on the type, length and linkage of a carbohydrate components as well as the degree of saturation of potential glycosylation sites on the protein itself. Carbohydrates can have a significant influence on the physicochemical properties of glycoproteins, affecting their folding, solubility, aggregation and degradation. Furthermore, glycan chains in glycoproteins play key roles in many biological processes such as embryonic development, immune response and cell-cell interactions in which sugar-sugar or sugar-protein specific recognition is involved (Wei & Li , 2009). Altered glycosylation is an universal feature of cancer cells, and certain glycan structures and glycoproteins are well-known tumor markers. These include for example glycoproteins such as carcinoembryonic antigen (CEA), commonly used as a marker of colorectal cancer, prostate-specific antigen (PSA) and CA-125 used in the diagnosis of ovarian cancer (Drake et al., 2010). High expression of some glycosyl epitopes for example sialyl Lewis a, sialyl Lewis x, Lewis y, promotes invasion and metastasis. Antibodies against Lewis antigens are used for evaluation of specimens from breast, bladder, colorectal, esophageal and lung carcinomas (Drake et al., 2010). Glycans can regulate different aspects of tumor progression, including proliferation, invasion and metastasis. Cancer-related changes in glycosylation can reflect disease specific alterations in glycan biosynthetic pathways. These include variations in the expression and activity of glycosyltransferases, enzymes that add monosaccharides to acceptors, i.e. proteins or growing carbohydrate chains and glycosidases which catalyze the hydrolysis of the glycosidic linkage to release sugars. There are three most common categories of protein glycosylation 1) N-glycosylation, where glycans are attached to asparagine residues in a consensus sequence N-X-S/T via N-acetylglucosamine (GlcNAc) residue; 2) O-glycosylation, where glycans are attached to serine or threonine via N-acetylgalactosamine (GalNAc) residue (mucin type glycosylation);

show abstract

Diagnosis of Recurrent Thyroid Cancer in Patients with Anti-thyroglobulin Antibodies

Ringel

Sipos

2016

Thyroid Cancer

View full text Add to dashboard Cite

Oncofetal Fibronectin mRNA Is Highly Abundant in the Blood of Patients with Papillary Thyroid Carcinoma and Correlates with High-Serum Thyroid-Stimulating Hormone Levels

Cited by 6 publications

References 25 publications

Serum Oncofetal Fibronectin (onfFN) mRNA in Differentiated Thyroid Carcinoma (DTC): Large Overlap between Disease-Free and Metastatic Patients

Serum Oncofetal Fibronectin (onfFN) mRNA in Differentiated Thyroid Carcinoma (DTC): Large Overlap between Disease-Free and Metastatic Patients

Glycosylation and Glycoproteins in Thyroid Cancer: A Potential Role for Diagnostics

Diagnosis of Recurrent Thyroid Cancer in Patients with Anti-thyroglobulin Antibodies

Contact Info

Product

Resources

About